real-time news and commentary for investors
Tuesday, Sep 17
BioLineRx gets patent allowance notice for BL-8020 in hepatitis C
- BioLineRx (BLRX) receives a notice of allowance for a patent covering the use of BL-8020 (which is basically an "improved" version of Ribavirin) "for treating HCV-infected patients non-responsive to an anti-HCV therapy."
- The protection is good through at least 2031.
- Expect a Phase 1/2 read-out in H1 2014.